Eli Lilly and Co. stock edges higher as analysts lift fair value estimates

Eli Lilly and Co. stock (ISIN US5324571083) closed at USD 1,152.62 on the New York Stock Exchange on September 18, 2026, only a fraction below recent highs and with modest daily gains of 0.02 percent per MarketBeat data.

Analyst targets and fair value move higher

According to MarketBeat on September 18, 2026, Eli Lilly and Co. stock carries a consensus price target of USD 1,305.25, implying about 13.2 percent upside from the closing price of USD 1,152.62.

The same overview shows that the shares have risen roughly 7.2 percent since the last analyst report used as a reference point, underlining that the current market price already reflects part of the optimism embedded in these targets.

As The Globe and Mail reported on September 19, 2026, Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Eli Lilly and Co. and set a price target of USD 1,284, compared with a share price of USD 1,152.44 at the prior close referenced in that note.

This Guggenheim target sits slightly below the broader average but still points to a double-digit percentage gain, highlighting that individual houses vary within a generally constructive view on the stock.

In parallel, fair value estimates have been adjusted upward: a recent analysis cited by Yahoo Finance on September 20, 2026 notes that Eli Lilly’s fair value has been raised from USD 1,297.31 to USD 1,325.39, adding another data point that supports a valuation range above the current market level.

Valuation debate and growth drivers

Against this backdrop, valuation remains a key debate for investors. According to GuruFocus on September 19, 2026, Eli Lilly and Co. shares trade at USD 1,152.93 versus a GF Value metric of USD 1,543.84, suggesting the stock is approximately 25.3 percent undervalued on that proprietary model.

The GF Value framework combines historical valuation multiples, past performance and analysts’ future expectations, and the gap between the GF Value and the current price indicates that, under those assumptions, there could be substantial upside if earnings and cash flows evolve as projected.

At the same time, another perspective highlighted by Simply Wall St on September 19, 2026 examines whether Eli Lilly’s share price of about USD 1,152.93 is justified by the company’s future cash flow potential.

This analysis points out that over the last five years Eli Lilly has delivered a total return of roughly 4.2 times the initial investment, which raises the bar for future performance and makes investors more sensitive to any disappointment in growth or margins.

Growth expectations center primarily on obesity and oncology drugs. Research commentary collected by GetStockReport in September 2026 notes that Eli Lilly trades at about a 7.8 percent premium to its five-year median valuation while analyst targets sit roughly 15 percent higher than the current share price, with the investment case hinging on whether obesity treatments can sustain triple-digit growth and margin expansion into the next decade.

The same commentary underscores that Eli Lilly’s ability to maintain high growth rates in these key franchises will be crucial for justifying both current valuations and ambitious price targets, given that much of the stock’s rerating has already been driven by expectations rather than fully realized profits.

Legal and policy risks remain part of the picture as well. According to GuruFocus, the GF Value assessment explicitly incorporates concerns around legal issues and regulatory changes in drug pricing, factors that could compress margins or slow growth if they materialize.

Latest reported figures and historical context

While the current week’s sources focus mainly on valuation, price targets and growth narratives, they also refer back to the strong fundamentals that have driven Eli Lilly’s multi-year rerating.

Analytical notes summarized by Simply Wall St mention that the company’s five-year total return of about 4.2 times was supported by rapid earnings growth and multiple expansion, particularly as new obesity and diabetes treatments gained traction.

Although specific quarterly revenue and earnings figures for 2026 are not detailed in this week’s coverage, the valuation models discussed are based on the most recent company guidance and consensus forecasts, implying that the forward-looking numbers used by analysts remain anchored in up-to-date internal and external expectations.

For investors, the core takeaway is that Eli Lilly’s fundamentals and pipeline have shifted the company into the ranks of trillion-dollar healthcare names, which makes incremental changes in guidance or trial data particularly influential on the stock’s day-to-day moves.

Stock level near forecast ranges

From a chart perspective, Eli Lilly and Co. stock is trading close to levels used in medium-term forecasts. A price-based forecast published by LongForecast for September 2026 cites a beginning price of USD 1,158 with a projected range between USD 1,062 and USD 1,287 for the month.

With the actual closing price at USD 1,152.93 on September 18, 2026, the stock currently sits slightly below that forecast starting level and well within the indicated range, suggesting that recent trading behavior has broadly aligned with the modeled volatility corridor.

Market capitalization data reinforce the scale of the company. Tokenized and synthetic representations of Eli Lilly’s equity compiled by CoinMarketCap on September 18, 2026 indicate a market cap of about USD 1.02 trillion tied to the underlying shares, highlighting that the company ranks among the largest listed healthcare firms worldwide.

For shareholders, this scale can be both a stabilizing factor and a constraint: while large, diversified portfolios of drugs and indications can mitigate single-product risk, it also means that incremental percentage growth in earnings becomes harder to achieve from such a high base.

Eli Lilly and Co. stock stays supported above USD 1,150

At the last completed trading session on September 18, 2026, Eli Lilly and Co. stock closed at USD 1,152.62 on the New York Stock Exchange, with intraday trading leaving the price close to the USD 1,152.93 level cited in several valuation analyses and roughly 13 percent below the average analyst price target of USD 1,305.25.

More news and analyses on Eli Lilly and Co. stock